Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech giant Gilead Sciences (NASDAQ: GILD ) has earned a respected four-star ranking.
With that in mind, let's take a closer look at Gilead, and see what CAPS investors are saying about the stock right now.
Gilead facts
|
|
|
| Headquarters (founded) | Foster City, Calif. (1987) |
| Market Cap | $85.1 billion |
| Industry | Biotechnology |
| Trailing-12-Month Revenue | $10.0 billion |
| Management | Chairman/CEO John Martin President/COO John Milligan |
| Return on Equity (average, past 3 years) | 36.5% |
| Cash/Debt | $1.9 billion / $8.0 billion |
| Competitors | Bristol-Myers Squibb GlaxoSmithKline Pfizer |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 2,253 members who have rated Gilead believe the stock will outperform the S&P 500 going forward.
Just yesterday, one of those Fools, TMFTailwind, succinctly summed up the Gilead bull case for our community:
Very profitable company, and I expect [Gilead's] streak of profitability to continue to increase. No significant patent expiration until 2018. With the current success in the HIV market, if the company can find success in a new category via R&D efforts, this could turn out to be a big winner.
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Gilead may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
No comments:
Post a Comment